News & Videos - E-THERAPEUTICS ORD 0.1P

e-therapeutics is a UK biotech company using proprietary computational biology and RNAi platforms to discover novel disease ......

Edison Investment Research Limited Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery 13-Nov-2023 / 09:05 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 13 November 2023 Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery e-therapeutics reported H1 FY24 results (to end-July 2023), reaffirming its commitment to integrating its computational and hepatocyte biology expertise to develop...

e-therapeutics: Fundraise of £13.5 million PR Newswire LONDON, Sept. 30, 2022 LONDON , Sept. 30, 2022 /PRNewswire/ -- e-therapeutics plc (AIM: ETX) (OTC-QX: ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased to announce a fundraise of £13.5 million before expenses by way of a subscription for new ordinary shares of 0.1p each ("Ordinary Shares") in the Company (the "Subscription") at a price of 20p per Ordinary Share by...

e-therapeutics: Fundraise of £13.5 million PR Newswire LONDON, Sept. 30, 2022 LONDON , Sept. 30, 2022 /PRNewswire/ -- e-therapeutics plc (AIM: ETX) (OTC-QX: ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased to announce a fundraise of £13.5 million before expenses by way of a subscription for new ordinary shares of 0.1p each ("Ordinary Shares") in the Company (the "Subscription") at a price of 20p per Ordinary Share by...

OTC Markets Group Welcomes e-therapeutics plc to OTCQX PR Newswire NEW YORK, Sept. 24, 2021 NEW YORK , Sept. 24, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced e-therapeutics plc (AIM: ETX) (OTCQX: ETXPF), a UK based company specialist in computational drug discovery with a focus on developing RNA interference ('RNAi') therapeutics, has qualified to trade on the OTCQX ® Best Market. e-therapeutics...

Edison Investment Research Limited Edison issues update on e-Therapeutics (ETX) 05-March-2019 / 15:51 GMT/BST London, UK, 5 March 2019 Edison issues update on e-Therapeutics (ETX) e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. Both R&D and...

Edison Investment Research Limited Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX) 12-Dec-2018 / 13:01 GMT/BST London, UK, 12 December 2018 Edison issues outlook on e-Therapeutics (ETX) e-Therapeutics (ETX) has announced a long-awaited research collaboration with Novo Nordisk (Novo) on early target discovery in diabetes. This is the first commercial collaboration in ETX's history and will last for at least a year. The financial terms of the transaction were not...

Edison Investment Research Limited Edison Investment Research Limited: Edison issues update on e-Therapeutics (ETX) 06-Dec-2018 / 10:35 GMT/BST London, UK, 6 December 2018 Edison issues update on e-Therapeutics (ETX) e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson's disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information...

Edison Investment Research Limited Edison issues update on e-Therapeutics (ETX) 08-Oct-2018 / 10:42 GMT/BST London, UK, 8 October 2018 Edison issues update on e-Therapeutics (ETX) e-Therapeutics' (ETX:LN) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was...

Edison Investment Research Limited Edison issues update on e-Therapeutics (ETX) 05-Oct-2017 / 11:34 GMT/BST London, UK, 5 October 2017 Edison issues update on e-Therapeutics (ETX) e-Therapeutics' (ETX) interim numbers demonstrate tight cost control and focus on the rationalised pipeline, with continued investment into the Network-Driven Drug Discovery platform. In the near term, we should see positive data to support out-licensing of its immuno-oncology projects. The company is well-positioned...

e-Therapeutics (EXT) is a UK-based drug discovery company that has developed a proprietary, computer-based discovery platform based on network biology....